Get Ahead with IPO Insights, IPO Prophet

IPO Prophet

Get Ahead with IPO Insights

At IPO Prophet®, our team leverages over three decades of expertise to deliver actionable quantitative analytics for the IPO market in real-time. This platform synthesizes our extensive experience investing in IPOs, providing investors with revolutionary tools to navigate the complexities of issuance day. Our mission is to empower investors with data-driven insights to make more informed decisions.

Equity Capital Markets

Blossomhill Therapeutics / Equity Capital Markets

<ul><li>BlossomHill Therapeutics is expected to list on the Nasdaq under the ticker BLSM, offering 7.82 million shares at a price range of $15.00 to $17.00 per share and targeting approximately $125 million in gross proceeds.</li><li>The company is developing next-generation macrocyclic small-molecule oncology therapies designed to overcome resistance mechanisms in EGFR-mutant cancers.</li><li>Its lead candidate, BH-30643, is being evaluated in a global Phase 1/2 study targeting patients with EGFR-mutant non-small cell lung cancer, including difficult-to-treat resistance mutations.</li></ul>

BlossomHill Therapeutics is expected to list on the Nasdaq under the ticker BLSM, offering 7.82 million shares at a price range of $15.00 to $17.00 per share and targeting approximately $125 million in gross proceeds.The company is developing next-generation macrocyclic small-molecule oncology therapies designed to overcome resistance mechanisms in EGFR-mutant cancers.Its lead candidate, BH-30643, is being evaluated in a global Phase 1/2 study targeting patients with EGFR-mutant non-small cell lung cancer, including difficult-to-treat resistance mutations.

IPO Rating: BlossomHill Therapeutics (BLSM)

US IPOs and Secondary Offerings, IPO Boutique

IPO Boutique

US IPOs and Secondary Offerings

For more than 20 years, we have been providing research, analysis, commentary and ratings on US Equity Capital Markets to institutional investors (US IPOs and Secondary Offerings). Our vast network of contacts across the Equity Capital Markets and attention-to-detail sets us apart from our competitors.

Since 2012, we have achieved a successful hit rating on 89% of Buy-rated IPOs. The collective “Buy” ratings averaged a first trade of 16.3% above issue.Our Neutral Rated Deals averaged just 2% above the issue price at first trade.

Our written research includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

In addition, we provide a high-touch premium desk access which includes analyst access, as well as real time insights on US IPOs as well as secondary offerings.

IPOs and Secondary Offerings

<ul>
<li>BlossomHill is advancing a precision oncology pipeline led by BH-30643, an OMNI-EGFR inhibitor targeting resistant EGFR-mutant NSCLC populations.</li>
<li>IPO proceeds will primarily fund BH-30643’s Phase 1/2 SOLARA trial and potential registrational Phase 2 development pathway.</li>
<li>Backed by notable biotech investors, BlossomHill enters public markets as an early-stage oncology company with significant clinical execution risk and upside potential.</li>
</ul>


BlossomHill is advancing a precision oncology pipeline led by BH-30643, an OMNI-EGFR inhibitor targeting resistant EGFR-mutant NSCLC populations.
IPO proceeds will primarily fund BH-30643’s Phase 1/2 SOLARA trial and potential registrational Phase 2 development pathway.
Backed by notable biotech investors, BlossomHill enters public markets as an early-stage oncology company with significant clinical execution risk and upside potential.


BlossomHill Therapeutics (BLSM): Phase 1/2 Lung Cancer Biotech Sets Terms for IPO, Debuting Friday

Latigo Biotherapeutics / Equity Capital Markets

<ul><li>The IPO market showed signs of its traditional late-summer slowdown Friday as Latigo Biotherapeutics (LTGO) and BlossomHill Therapeutics (BLSM) made their Nasdaq debuts. Both biotechnology offerings found enough support to avoid significant breaks below their IPO prices by the close, but neither produced the sustained aftermarket momentum that characterized some of the stronger new issues earlier this summer.</li><li>Latigo priced 19.2 million shares at $18.00, raising approximately $346 million, and opened at $21.00, a 16.7% premium to its IPO price.</li><li>The shares initially traded as high as $22.47, but the early strength quickly faded. LTGO ultimately closed at $18.25, down 13.1% from its opening trade and just 1.4% above its IPO price, on approximately 2.59 million shares of volume.</li></ul>

The IPO market showed signs of its traditional late-summer slowdown Friday as Latigo Biotherapeutics (LTGO) and BlossomHill Therapeutics (BLSM) made their Nasdaq debuts. Both biotechnology offerings found enough support to avoid significant breaks below their IPO prices by the close, but neither produced the sustained aftermarket momentum that characterized some of the stronger new issues earlier this summer.Latigo priced 19.2 million shares at $18.00, raising approximately $346 million, and opened at $21.00, a 16.7% premium to its IPO price.The shares initially traded as high as $22.47, but the early strength quickly faded. LTGO ultimately closed at $18.25, down 13.1% from its opening trade and just 1.4% above its IPO price, on approximately 2.59 million shares of volume.

Summer Doldrums Set In as Latigo (LTGO) And BlossomHill (BLSM) Close Out a Quieter Week

United States

Blossomhill Therapeutics, Inc. is a biopharmaceutical company. The Company develops small molecule medicines that address unmet medical needs in cancer treatment. Blossomhill Therapeutics operates in the United States.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Blossomhill Therapeutics (BLSM US)

IPO Rating: BlossomHill Therapeutics (BLSM)

BlossomHill Therapeutics is expected to list on the Nasdaq under the ticker BLSM, offering 7.82 million shares at a price range of $15.00 to...

IPO Prophet

BlossomHill Therapeutics (BLSM): Phase 1/2 Lung Cancer Biotech Sets Terms for IPO, Debuting Friday

BlossomHill's precision oncology pipeline, led by BH-30643, targets resistant EGFR-mutant NSCLC populations with IPO proceeds funding Phase 1/2...

IPO Boutique

Summer Doldrums Set In as Latigo (LTGO) And BlossomHill (BLSM) Close Out a Quieter Week

Latigo surrendered most of its opening premium while BlossomHill finished back at its IPO price, as the new-issue market loses some seasonal...

IPO Prophet

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

IPO Rating: BlossomHill Therapeutics (BLSM)

BlossomHill Therapeutics is expected to list on the Nasdaq under the ticker BLSM, offering 7.82 million shares at a price range of $15.00 to...

IPO Prophet

BlossomHill Therapeutics (BLSM): Phase 1/2 Lung Cancer Biotech Sets Terms for IPO, Debuting Friday

​BlossomHill's precision oncology pipeline, led by BH-30643, targets resistant EGFR-mutant NSCLC populations with IPO proceeds funding Phase 1/2...

IPO Boutique

Summer Doldrums Set In as Latigo (LTGO) And BlossomHill (BLSM) Close Out a Quieter Week

Latigo surrendered most of its opening premium while BlossomHill finished back at its IPO price, as the new-issue market loses some seasonal...

IPO Prophet

BlossomHill's precision oncology pipeline, led by BH-30643, targets resistant EGFR-mutant NSCLC populations with IPO proceeds funding Phase 1/2...